IgIQ: Your Single Source for Ig Solutions

Welcome to IgIQ, a comprehensive resource center for people who depend on CSL Behring's immune globulin (Ig) therapies.

IgIQ gathers many Ig resources under one roof, making it easy to get the guidance and support you need with a single phone call. Our friendly and knowledgeable staff can:

  • Answer general (non-medical) questions
  • Provide helpful resources
  • Enroll you in peer support and financial assistance programs
  • Answer questions related to insurance coverage

Have Questions?

To get the guidance and support you need,
Call 1-877-355-IGIQ (4447)
Monday–Friday, 8 AM to 8 PM ET

Need help paying for Hizentra?

Hizentra Co-Pay Relief Help for new and existing Hizentra patients
The Hizentra Co-Pay Relief program helps eligible patients afford their therapy by helping with monthly out-of-pocket expenses for Hizentra (up to $5,000 for one year, with no monthly cap*).

To be eligible:

  • Prescription must be for primary immunodeficiency diagnosis
  • Patients must be at least 2 years of age
  • Patient must be receiving Hizentra through a specialty pharmacy or physician office
  • It is recommended that the patient use a Specialty Pharmacy provider that is in-network with the patient's current plan
  • Patient must express financial need
  • Patient must have coverage for the product under a private US insurance plan. Not valid for prescriptions eligible for reimbursement by any federal or state healthcare program, such as Medicare, Medicare advantage plans, Medicaid, PCIP, Champus, TriCare, Veterans Administration (VA), or any other state or federal program
  • Patients whose insurance policy prohibits co-pay assistance are not eligible
  • This program is subject to change or discontinuation by CSL Behring at any time, for any reason, and with or without prior notice
  • Hizentra Co-Pay Relief program is administered by Medmonk Inc., terms and conditions apply

It’s easy
Enrollment happens seamlessly at the Specialty Pharmacy. Patients interested in receiving co-pay assistance, must contact their Specialty Pharmacy, express their need for financial assistance and ask the pharmacy to enroll them by requesting Hizentra Copay Assistance via Medmonk. Patients can contact CSL Behring's IgIQ* Resource Center at 1-877-355-IGIQ (4447) or visit www.Hizentra.com/copay for additional information.

*Other terms and conditions may apply.

This program applies to product costs only; however, assistance for infusion-related costs may be available through a non-profit patient support organization. Contact IgIQ to learn more.

Prior to enrolling in this CSL Behring program, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their insurance carrier’s requirements.

Protect yourself from a lapse in coverage.

CSL Behring Assurance CSL Behring understands the stress and hardship caused by a lapse in health insurance. CSL Behring AssuranceSM is designed to help ensure that people who rely on our Ig therapies can continue to receive treatment even if they experience a lapse in third-party, private health insurance.

Benefits for Patients
Patients earn CSL Behring Assurance points for every month of continuous Ig product use. The points are redeemable for Ig therapy in the event you lose insurance coverage. Points are issued based on product use from the date that enrollment eligibility is approved, so it’s important to enroll as soon as possible.


  • Enrollment is free
  • Simply contact your IgIQ Care Coordinator


  • Earn a point for every consecutive month of product use.
  • Redeem 3 points for a one‐month supply of your CSL Behring product.
  • If you suffer a lapse in your insurance simply contact a CSL Behring Assurance Care Coordinator and we will take care of the rest.

Certain limitations apply—see program Terms and Conditions for additional information.

Ensure access to treatment during difficult times.

CSL Behring Biotherapies for Life Access to treatment during difficult times
Periodically, patients with chronic illnesses are faced with difficult insurance situations that may prevent access to life-sustaining therapies.

The CSL Behring Patient Assistance ProgramSM provides Hizentra free of charge if you do not have prescription drug insurance or have been denied coverage by your insurance company and meet specific financial and medical criteria.

  • Qualified patients may receive up to a 3-month supply of their Ig product
  • At the end of 3 months, the patient’s eligibility is re-evaluated for continued participation in the program, if needed
  • Emergency needs are addressed under a separate process when a call is received within 24 hours of the emergency

Your Comprehensive Library of Resources

We know how overwhelming living with PI can be. So we've assembled a comprehensive library of resources to help you throughout your journey.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Patient/Caregiver IgIQ Support Services
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and MyHizentra® are registered trademarks of CSL Behring AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM, IgIQSM, and Premier StartSM are service marks of CSL Behring LLC.
Voice2Voice® is a registered trademark of CSL Behring GmbH.
IgIQSM is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM and CSL Behring Patient Assistance ProgramSM are service marks of CSL Behring LLC.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0316-MAR18